Prophylaxis of bleeding episodes in patients with von Willebrand's disease

Blood Transfusion

Volumn 6, Issue SUPPL. 2, 2008, Pages

  Federici, Augusto B ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bleeds; Retrospective and prospective clinical trials; Secondary long term prophylaxis; Von Willebrand factor factor VIII concentrates; Von Willebrand's disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; VON WILLEBRAND FACTOR;

ABSENCE OF SIDE EFFECTS; AMINO TERMINAL SEQUENCE; ANEMIA; BLEEDING; BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIABETES INSIPIDUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HOSPITALIZATION; HUMAN; ITALY; LONG TERM CARE; MENORRHAGIA; PLASMA; PREVALENCE; PROPHYLAXIS; PROSPECTIVE STUDY; RECURRENT DISEASE; SEPTICEMIA; SWEDEN; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; TOOTH EXTRACTION; TREATMENT RESPONSE; VON WILLEBRAND DISEASE;

CLINICAL TRIALS AS TOPIC; DEAMINO ARGININE VASOPRESSIN; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; EPISTAXIS; FACTOR VIII; FEMALE; FIBRINOGEN; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HEMORRHAGE; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 56649115781     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0034-08     Document Type: Conference Paper

References (33)

1. Federici AB, Mannucci PM. Management of Inherited von Willebrand disease in 2007. Ann Med 2007; 39:133-9.
2. Lee CA, Kessler CM (eds). Proceedings of a Nordic von Willebrand Symposium. Haemophilia 1999; 5 (suppl 2): 1-12
3. th anniversary of von Willebrand disease: history, management, research. Haemophilia 2006; 12:563-72.
4. Sadler JE, Budde U, Eikenboom JCJ, et al. Update on the pathophysiology and classification of von Willebrand disease. A report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-14.
5. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of VWD in Italy. Haemophilia 2002; 8: 607-21.
6. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004; 10: 169-76.
7. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007;109:112-21.
8. Silwer J. von Willebrand's disease in Sweden Acta Paediat Scand 1973; 238: 1-159.
9. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 348 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111:1223-9.
10. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power ofbleeding history for the diagnosis of von Willebrand disease type 1: an international multicenter study. J Thromb Haemost 2005; 3: 2619-26.
11. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 of von Willebrand disease: results from a multicenter European Study (MCMDM-1VWD). J. Thromb Haemost 2006; 4: 766-73.
12. Federici AB, Bucciarelli P, Castaman G, et al. Prevalence and determinants of bleeding in different types of von Willebrand disease: results of the first prospective multicenter study on 814 Italian patients. Blood 2007; 111:219a,Abstract 714.
13. Mannucci PM. Treatment of von Willebrand disease. N Eng J Med 2004; 351:683-94.
14. Cash JD, Garder AMA, Da Costa J. The release of plasminogen activator and factor VIII by LVP,AVP, DDAVP, ATIII and OT in man. Br J Haematol 1974; 27: 363-4.
15. Hashemi S, Palmer DS, Aye MT, Ganz PR. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor releases from endothelial cells. J Cell Physiol 1993; 154:496-505.
16. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. A new pharmacological approach to the management of hemophilia and von Willebrand disease. Lancet 1977; 1:869-72.
17. Federici AB. The use of desmopressin in von Willebrand disease: the first 30 years (1977-2007). Haemophilia 2008; 14 (Suppl 1):5-14.
18. Federici AB, Mazurier C, Berntorp E, et al. Biological response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103:2032-8.
19. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagulation and Fibrinolysis 2005; 16: S17-S21.
20. Dobrovska A, Krzensk U Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998;4:33-9.
21. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10:243-9.
22. Schimpf K, Mannucci PM, Kreutz W. Absence of hepatitis after treatment with a pasteurised factor VIII concentrate and no previous transfusions. N Engl J Med 1987; 316: 918-22.
23. Schimpf K, Brackmann H H, Kreutz W. Absence of anti human immunodeficiency virus types 1 and 2 seroconversion after the treatment of haemophilia A or VWD with pasteurized factor VIII concentrate. N Engl J Med 1989; 321: 1148-52.
24. Kreuz W, Auerswald G, Bruckmann C, et al. Prevention of hepatitis C virus infection in children with haemophilia A and B and von Willebrand's disease. Thromb Haemost 1992;67:184.
25. Federici AB, Santagostino E., Rumi MG, et al. The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study. Haematologica 2006; 91:503-8.
26. Lillicrap D, Poon MC, Walker I, et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002;87:224-30.
27. Franchini M, Rossetti G, Tagliaferri A, et al. Efficacy and safety of factor VIII/von Willebrand factor concentrate, Haemate-P, in preventing bleeding during surgery or invasive procedures in patients with von Willebrand's disease. Haematologica 2003;88:1279-83.
28. Cox Gill J, Ewenstein BM, Thompson AR, et al. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/von Willebrand factor concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003; 9:688-95.
29. Thompson AR, Gill JC, Ewenstein BM, et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/von Willebrand factor concentrate (Humate-P). Haemophilia 2004;10:42-51.
30. Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate-P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica 2007; 92:944-51.
31. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002;88:378-9.
32. Berntorp E, Petrini P. Long-term prophylaxis in von WiUebrand disease. Blood Coag Fibrin 2005; 16: S23-S26.
33. Federici AB, Gianniello F, Canciani MT, Mannucci PM. Secondary long-term prophylaxis in severe patients with von Willebrand disease: an Italian cohort study. Blood 2005; 106: 507a, abstract 1782.